相关实验视频

Updated: Mar 10, 2026

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function

Published on: February 27, 2019

在非小细胞肺癌的进展后重新挑战免疫疗法:系统性审查和网络元分析

Ying Li¹, Junfeng Zhao², Jiaxuan Chen³

¹Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.

|March 9, 2026

概括

在疾病进展后继续免疫疗法重试显著改善了晚期非小细胞肺癌 (NSCLC) 患者的生存率. 将免疫检查点抑制剂与抗血管原治疗结合起来,提供了最好的无进展生存结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
临床试验临床试验

背景情况:

晚期非小细胞肺癌 (NSCLC) 对长期治疗提出了挑战.
在NSCLC中,最初的免疫疗法反应可能会随着疾病的进展.

研究的目的:

评估在晚期NSCLC中疾病进展后继续免疫治疗的疗效.
在NSCLC患者中确定免疫疗法再挑战的最佳治疗方案.

主要方法:

临床研究的系统审查和元分析.
将患者分为免疫疗法再挑战和非免疫疗法组.
使用危险比率 (HR) 分析无进展生存 (PFS) 和整体生存 (OS).

主要成果:

免疫疗法重新挑战显著改善了PFS (HR:0.65,p=0.004) 和OS (HR:0.69,p=0.013).
免疫检查点抑制剂 (ICI) 加上抗血管原治疗的联合治疗在再挑战组中显示出优异的PFS.

结论:

持续免疫疗法再挑战是晚期NSCLC患者进展后有益的策略.
基于ICI的组合疗法,特别是与抗血管原剂的组合疗法,是NSCLC的有效治疗方法.
这些发现可能会为更新的肺癌免疫治疗指南提供信息.

关键词:

卫生科学卫生科学医学专业的医学专业.医学医学医学医学医学瘤学在瘤学方面.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.